Manufacturing: Page 2


  • Header image
    Image attribution tooltip
    Permission granted by MilliporeSigma
    Image attribution tooltip
    Sponsored by MilliporeSigma

    From bench to batch: AAV manufacturing for the next-generation of gene therapies

    Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.

    July 21, 2025
  • Ai laboratory equipment sterilizes items.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Private equity firms back PCI Pharma in bet on drug production

    The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

    By July 14, 2025
  • Resilience will manufacture mRNA for Moderna’s COVID-19 Vaccine at its facility in Mississauga, Ontario, Canada.
    Image attribution tooltip
    Courtesy of National Resilience; Business Wire
    Image attribution tooltip

    National Resilience, a well-funded manufacturing startup, to scale back operations

    The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”

    By June 10, 2025
  • Two individuals in full-body cleanroom suits walk through a sterile, modern pharmaceutical or biotechnology facility
    Image attribution tooltip
    Permission granted by Resilience
    Image attribution tooltip
    Sponsored by Resilience

    Navigating the evolving landscape of fill/finish: Challenges and what’s ahead

    The demand for fill/finish services has never been greater, how are CDMOs responding?

    May 27, 2025
  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo pressures GLP-1 compounders as FDA ban takes hold

    The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have dented its sales forecasts.

    By Kristin Jensen • May 22, 2025
  • Illustration of medical pills
    Image attribution tooltip
    Permission granted by PHIL
    Image attribution tooltip
    Sponsored by PHIL

    Bridging the data gaps that impact retail and specialty-lite success

    Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.

    May 19, 2025
  • Lab worker all suited up in protective gear doing tests
    Image attribution tooltip
    Permission granted by West Pharmaceutical Services
    Image attribution tooltip
    Sponsored by West Pharmaceutical Services

    How regulatory convergence is raising the bar for sterile drug safety—and how West leads the way

    Global regulators continue to raise the bar on sterile drug manufacturing—and West is responding.

    May 19, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip
    Pharma reshoring

    Sanofi to pour more than $20B into US drug research and manufacturing

    The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could change amid shifting Trump administration policies.

    By Kristin Jensen • May 15, 2025
  • A sign showing Gilead's logo
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pharma reshoring

    Gilead, bracing for tariffs, joins peers in US drug production push

    The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and operational investments in U.S. drug manufacturing.

    By Kristin Jensen • May 8, 2025
  • U.S. President Donald Trump, accompanied by Food and Drug Administration Commissioner Marty Makary (L), National Institutes of Health Director Jayanta Bhattacharya (2nd-L), Health and Human Services Secretary Robert F. Kennedy Jr. (2nd-R) and Domestic Policy Council Director Vince Haley (R), signs an executive order in the Oval Office at the White House on May 05, 2025 in Washington, DC
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Trump orders FDA to help speed building of new drug factories

    Yet regulatory relief for U.S. expansion could be accompanied by new tariffs and drug pricing rules.

    By May 6, 2025
  • Two people in business suits stand by a window looking at third person blurred in the foreground.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pharma reshoring

    Pharma downplays tariff threat, even as risks remain unclear

    Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.

    By Ned Pagliarulo , May 1, 2025
  • U.S. President Donald Trump holds up a chart while speaking during a "Make America Wealthy Again" trade announcement in the Rose Garden at the White House on April 2, 2025.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    Merck takes $200M tariff hit, trimming its gross profits

    The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond. 

    By April 24, 2025
  • A sign spelling Roche hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip
    Pharma reshoring

    Roche, answering tariff threat, pledges $50B to US drug production

    The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S., among them a gene therapy plant in Pennsylvania.

    By April 22, 2025
  • A person speaks at a podium in front of a large, out-of-focus painting.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    US launches probe that could set stage for pharma tariffs

    The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S. importing pharmaceuticals and their starting materials.

    By Ned Pagliarulo • Updated April 14, 2025
  • A sign spelling Novartis hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pharma reshoring

    Amid tariff turmoil, Novartis commits to spending $23B on US manufacturing

    Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.

    By April 10, 2025
  • President Donald Trump delivers remarks during a Cabinet meeting at the White House on April 10, 2025 in Washington, DC.
    Image attribution tooltip
    Anna Moneymaker / Staff via Getty Images
    Image attribution tooltip
    Trump administration

    Trump pauses most reciprocal tariffs, hikes China’s further

    Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the broader market. 

    By Phil Neuffer • April 9, 2025
  • A man holds smiles with an open mouth at the camera as he holds up a sign reading "reciprocal tariffs" and listing multiple countries and percentage amounts.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip
    Trump administration

    Medtech industry pressures White House to exempt devices from tariffs

    AdvaMed and other healthcare groups have pleaded for the Trump administration to exempt medical devices and critical supplies.

    By Ricky Zipp • April 8, 2025
  • A person wearing gloves hangs a clear bag with fluid on a metal hook.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tariffs send healthcare industry into ‘unchartered waters’

    Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create disruptions to patient care.

    By Susanna Vogel • April 4, 2025
  • President Donald Trump waves to a crowd at the White House on April 2, 2025.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    Trump installs sweeping new tariffs, but pharma dodges blow

    The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical goods appear to be exempt, at least for now.

    By Phil Neuffer • Updated April 3, 2025
  • Joaquin Duato, CEO of Johnson & Johnson, testifies before the Senate Health, Education, Labor, and Pensions Committee at the Dirksen Senate Office Building on February 08, 2024 in Washington, DC. The Committee held the hearing to investigating the cost of prescription drugs. (Photo by Kevin Dietsch/Getty Images)
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Pharma reshoring

    J&J boosts US manufacturing as big pharma reshores

    Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

    By March 21, 2025
  • Medical lab technician illustration
    Image attribution tooltip
    Permission granted by Qiagen
    Image attribution tooltip
    Sponsored by QIAGEN Digital Insights

    NGS is changing GxP compliance. Will you adapt?

    Discover NGS for GxP compliance with full audit trails, operational control and robust data security.

    By QIAGEN Digital insights • March 17, 2025
  • CordenPharma’s Integrated Supply from peptide drug substance to injectable and oral solid dosage manufacturing.
    Image attribution tooltip
    Courtesy of CordenPharma
    Image attribution tooltip

    Viking inks CordenPharma deal to boost obesity drug supply

    The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.

    By March 11, 2025
  • A woman in scrubs standing next to manufacturing equipment in a large room filled with scientific steel equipment
    Image attribution tooltip
    Courtesy of Merck Manufacturing Division Durham, North Carolina, HPV facility ribbon cutting
    Image attribution tooltip

    Merck opens $1B vaccine plant in North Carolina

    Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.

    By March 11, 2025
  • A graphic designed image of DNA
    Image attribution tooltip
    Permission granted by Syngene
    Image attribution tooltip
    Sponsored by Syngene

    SynWeave™: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability

    Enhancing manufacturability is crucial for reducing the risks associated with scaling production.

    March 10, 2025
  • A person speaks from a podium on stage, flanked by red banners.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip
    Pharma reshoring

    Lilly CEO wields manufacturing plans to push pharma-friendly policies

    While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and changes to Medicare's drug negotiation program.

    By Ned Pagliarulo • Feb. 26, 2025